Nashat Amir

Camp4 Director Nashat Amir bought 1,307,189 shares for $1,999,999.17 at $1.53 on 2025-09-11; 6-insider cluster buy

Nashat Amir, Camp4 Therapeutics Director, executed 2 separate purchases totaling 1,307,189 shares for $1,999,999.17 at $1.53, resulting in a post-transaction holding of 197,661 shares. The stock trades at $2.78 currently, down 76.3% from its 52-week high of $11.74, though up 101.4% over the past 30 days. Amir's prior same-ticker buy on 2024-10-15 saw negative returns at both 30-day (-12.6%) and 90-day (-64.1%) horizons, with zero wins across his cross-ticker open-market purchase history. The filing occurs within a broader cluster pattern: 6 other insiders also bought within the past 14 days, suggesting coordinated or mutually reinforcing acquisition timing. Against this backdrop, Camp4 reports severe operating losses ($-12,587,000.00 net income in the latest quarter) despite strong annual revenue growth of 86.3%, leaving the unprofitable biotech's strategic direction and near-term cash position as critical factors for monitoring.

Director Nashat Amir purchases 909.1K shares of CAMP at $11.00 in $10.0M acquisition; 6 other insiders also bought within 14 days.

Director Nashat Amir acquired 909,090 shares at $11.00 on 2024-10-15 for a total investment of $9,999,990.00, representing his first substantial position in Camp4 Therapeutics. The filing contains a derivative-conversion notation indicating that Table II (derivative securities) holds his actual total position, and the 909.1K shares shown represent only the converted portion. This transaction is part of a cluster pattern: 6 other insiders executed purchases within the same 14-day window, indicating coordinated insider accumulation activity. The current stock price of $10.75 sits at the upper bound of the 52-week range ($0.40–$10.75), suggesting the stock has recovered substantially from lows. The timing and scale of this acquisition—alongside the concurrent insider buying cluster—warrants investor attention as an indicator of board-level confidence in company trajectory, though the full scope of Amir's derivative-adjusted holdings remains to be disclosed in Table II.